跳至主要内容
临床试验/NCT03906175
NCT03906175已完成不适用

Whole-body Hyperthermia for Mild to Moderate Depressive Disorder - a Randomized Controlled Tiral

Universität Duisburg-Essen2 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2019年6月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
46
试验地点
2
主要终点
Depression Severity: clinician-rated

研究概览

简要总结

The primary aim of this study is to investigate the effectiveness of whole-body hyperthermia in comparison to wait list on depressive symptom severity in patients with mild to moderate depressive disorder currently not under psychotherapeutic or antidepressant drug treatment.

Secondary aims included further quality of life outcomes, immunological parameters, and tolerability/safety of the hyperthermia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Unipolar depression (diagnosed according to the DSM-IV)
  • Mild depression: 8-16 points on the HAMD-17 or moderate depression: 17-23 points on the HAMD-17

排除标准

  • Current psychotherapy
  • Antidepressant drug treatment in the last 4 weeks before study inclusion
  • Participants who did not respond to prior antidepressant drug treatment, electroconvulsive therapy, or sleep deprivation (therapy-resistant depression)
  • Acute suicidality
  • Prior treatment with whole-body hyperthermia
  • Contraindications to hyperthermia treatment: acute or feverish infections, severe cardiovascular diseases (e.g. angina pectoris, heart failure, thrombosis, bleeding diathesis), severe gastrointestinal diseases (e.g. renal insufficiency, hepatitis, liver cirrhosis, peptic ulcer), severe neurological diseases (e.g. epilepsy, multiple sclerosis, cerebrovascular malformations or brain tumors), severe endocrine diseases (e.g. hyperthyroidism), or oncological diseases without remission
  • Participants taking anti-inflammatory or immunosuppressive drugs
  • Participants with severe psychiatric comorbidities (e.g. schizophrenia, schizoaffective disorder, bipolar disorder, dementia, ADHD, obsessive-compulsive disorder, PTSD, alcohol or drug addiction)
  • Women during pregnancy and breastfeeding
  • Lack of ability to consent

结局指标

主要结局

Depression Severity: clinician-rated

时间窗: week 6

Hamilton Rating Scale for Depression (HAMD-17)

次要结局

  • Global improvement: clinician-rated(week 6)
  • Fatigue: patient-rated(week 12)
  • Global Improvement: clinician-rated(week 12)
  • Stress: patient-rated(week 12)
  • Biomarkers: tumor necrosis factor alpha(week 12)
  • Biomarkers: high-sensitivity C-reactive protein(week 12)
  • Biomarkers: tryptophan(week 12)
  • Biomarkers: kynurenine(week 12)
  • Biomarkers: neopterin(week 12)
  • Biomarkers: interleukin 2(week 12)
  • Depression Severity: clinician-rated(week 12)
  • Depression Severity: patient-rated(week 12)
  • Global Functioning: clinician-rated(week 12)
  • Quality of Life: patient-rated(week 12)
  • Biomarkers: interleukin 6(week 12)
  • Biomarkers: interleukin 10(week 12)
  • Biomarkers: soluble intercellular adhesion molecule-1(week 12)
  • Adverse Events(week 12)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Holger Cramer

Research Director

Universität Duisburg-Essen

研究点 (2)

Loading locations...

相似试验